NICE conference networking 6.PNG

NICE Conference header image 2

Please find the agenda for the conference below. Speaker details will be updated throughout the run up to the conference.

Our programme has been built around three key themes. To find out which sessions fall into each theme, please click register now where you will be able to view this in more detail.

  • Life sciences – value and vision​
  • Digital health
  • Patient-centred quality care


Monday 25 June 2018


Pre-conference networking reception and Shared Learning Awards
Conference venue
Presented by Sir David Haslam, Chair, NICE


Tuesday 26 June 2018

08:00 – 09:00

Registration and refreshments

09:00 – 09:15

Chair’s welcome
Sir David Haslam
, Chair, NICE

09:15 – 10:15

Uniting the science and practice of clinical improvement

  • How do you link the guidance and evidence to improve care?
  • Role of evidence in setting clinical policy and designing care pathways
  • Tensions between financial pressures and quality improvement

​​Professor Martin Marshall, Professor of Healthcare Improvement, UCL
Professor Gill Leng, Deputy Chief Executive and Health and Social Care Director, NICE
Celia Ingham Clark
, Medical Director for Clinical Effectiveness, NHS England
Chaired by Dr Phil Hammond

10:15 – 10:45

Morning refreshments and networking

Morning Breakouts

10:45 – 11:45

Roadmap for life sciences – interactive workshop

  • Recap on what’s changed at NICE
  • How NICE’s Office for Market can help companies innovate – What is the journey?
  • NICE’s new approach to technology appraisals – speed to the market, effectiveness and cost
  • Affordability and the budget impact test – facilitating commercial conversations around costs

​​Carla Deakin, Associate Director, OMA, NICE
Jenniffer Prescott, CHTE Associate Director – Planning, operations and topic, NICE
Emily Crossley, CEO, Duchenne UK
Adam Burt
, Market Access and Public Affairs Director, Novo Nordisk
Chaired by Richard Vize, Director, Public Policy Media Ltd

Tackling antimicrobial resistance globally and locally

  • Demonstrating the value of new antimicrobials
  • NICE’s work to tackle growing resistance in clinical practice

Nick Crabb, Programme Director, Scientific Affairs, NICE
Susan Hopkins, Chair of ESPAUR, Public Health England
Tessa Lewis, Chair, NICE Committee
Chaired by Dr Phil Hammond


Getting it Right first time

  • Tailoring care to the individual while driving out unwarranted variation
  • Case study – how the Getting It Right First Time approach led to improved patient outcomes
  • Can clinical judgement and patient choice override NICE guidelines?
  • Looking at RightCare programme

​​Steve Sparks, NHS RightCare Delivery Partner, NHS England
Professor Tim Briggs, National Director of Clinical Quality and Efficiency, NHS Improvement
Suzanne Rankin
, CEO, Ashford and St. Peter's Hospitals NHS Foundation Trust​​ 
Chaired by Professor Gill Leng, Deputy Chief Executive and Health and Social Care Director, NICE


11.45 – 11.50

Transfer between breakout sessions

11:50 – 12:50

On the frontline of innovation – insights from the Cancer Drugs Fund

  • NICE’s approach to innovative treatments
  • New approaches to evidence and analysis
  • Benefits and risks for patients
  • Lessons for industry – balancing uncertainty around evidence access and cost

​​Dr Linda Landells, Associate Director, Technology Appraisals (Cancer Drugs Fund), NICE
David Thomson
Chemotherapy Pharmacist – NHS England Chemotherapy CRG & National Cancer Drug Fund
Eugene Benson, 
Associate Director of Market Access, Takeda
Chaired by Sir Andrew Dillon, CEO, NICE

Managing care for patients with multimorbidities – case studies of implementing NICE guidance

  • Assessment, prioritisation, and management of care for people with multiple long-term conditions
  • The NICE quality standard
  • Organising care around patient’s needs

Dr Amina Aitsi-Selmi, Honorary Senior Clinical Lecturer, Epidemioligy and Public Health, UCL
Steve Turner, Head of Medicines and Prescibing,

@Medicine Gov
Dr Deyo Okubadejo, chair for BGS East Anglia Region branch, British Geriatric Society
Chaired by Dr Phil Hammond

Shared decision-making and patient empowerment

  • What shared decision-making and empowerment mean for the doctor-patient relationship
  • NICE’s work around shared decision-making and patient decision aids 
  • How to introduce shared decision-making into practice
  • Managing the risks around empowering patients

Professor Gill Leng, Deputy Chief Executive and Health and Social Care Director, NICE
Professor Alf Collins, Clinical Director of Personalised Care, NHS England
Jo Jerrome
, CEO, Thrombosis UK
Chaired by Richard Vize, Director, Public Policy Media Ltd

12:50 – 13:50

Networking lunch

Lunch time sponsored fringe sessions

13:00 - 13:35

Increasing uptake of biologics: the role of biosimilars

Although many studies demonstrate the clinical benefits of biologics in the early phase of autoimmune disease, uptake of these treatments for patients with some conditions is variable in the UK. Hence we believe that this is the right time to discuss different approaches to increasing patient access to biologics based on the evidence of significant cost reduction of biologics after the introduction of biosimilars. 

Sponsored by Celltrion Healthcare

Research Opportunities with Canadian real world evidence 

Real world evidence can provide valuable insights and customised data solutions for patient-centric research. Many health systems capture a wide array of patient data on an ongoing basis; these data, collected for administrative purposes, are often referred to as “Real World Evidence (RWE)”. The lunchtime session will describe, in detail, the gamut of data available from Canadian health systems and the Medlior process for conducting RWE research studies.

Sponsored by
Medlior Health Outcomes Research

All sponsorship agreements exist between Dods Parliamentary Communications Ltd and the sponsor organisation. Sponsorship of the NICE Conference does not imply any endorsement by NICE of the sponsor organisation.

Afternoon Breakouts

13:50 -14:20

Implementing the Accelerated Access Review

  • Government’s plan for life sciences, including the Accelerated Access Collaborative to facilitate faster access to transformative products and simpler national and local routes to get products to patients
  • How NICE is supporting these developments.

Dr Samantha Roberts, Director of Innovation & Life Sciences, NHS England
Dr Paul Catchpole
, Value & Access Director, ABPI
Chaired by Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE

Behind the scenes in Greater Manchester

  • How devolution is changing clinical practice and leadership

Richard Preece, Executive Director, Quality First
Dr Tracey Vell, Associate Lead for Primary and Community Care, GM Health and Social Care Partnership
Chaired by Dr Phil Hammond



Apps and wearables

  • The potential for empowering patients and transforming care
  • Digital first public health – using digital tools to change the way Public Health England connects and interacts with people to improve public health
  • How NICE is approaching the evaluation of digitally enabled therapies for anxiety, depression and medically unexplained symptoms

Diarmaid Crean, Deputy Director, Digital, Public Health England
Harriet Unsworth
, Senior Technical Analyst, NICE
Chaired by Richard Vize, Director, Public Policy Media Ltd

14:20 – 14:25

Transfer between breakout sessions

14:25 – 14:55

HealthTech Connect – Speeding up adoption of innovative devices and diagnostics

  • What HealthTech Connect is and when it will be launched
  • The value of early interaction and how it will help tech innovators develop products and NHS organisations plan for adoption

Mirella Marlow, Programme Director, Devices and Diagnostic Systems, NICE
Donna Hakes, Programme Director, NHS England Specialised Services
Chaired by Andrew Davies, Market Access Director, ABHI

Keeping guidelines up to date: challenges and solutions

  • Upcoming changes to how NICE manages its guidelines
  • Surveillance and updates
  • Responding more quickly to important research
  • MAGICapp and its implication for guideline development

Professor Mark Baker, Director of the Centre for Guidelines, NICE
Chaired by Richard Vize, Director, Public Policy Media Ltd

What can big data analytics achieve for healthcare?

  • Using multiple types of data
  • Examining the most promising applications in clinical practice
  • Skills that healthcare teams will need to exploit big data

Michael Trenell, Director, National Institute for Health Research Innovation Observatory
Gary Leeming
, Chief Technology Officer, Connected Health Cities
Chaired by Dr Phil Hammond

14:55 – 15:00

Transfer between breakout sessions

15:00 – 15:50

Getting the most value out of medicines

  • Medicines value and the 5YFV
  • NICE support for medicines value and appropriate prescribing
  • Case study on implementing NICE guidelines

Paul Chrisp, Programme Director, Medicines and Technologies Programme, NICE
Su Jones, NHS Engagement Partner and National Lead for Accelerated Access and Reducing Variation, ABPI
​Dr Bruce Warner
, Deputy Chief Pharmaceutical Officer, NHS England
'Bunmi Fajemisin, MBA
, Lead Pharmacist - Medicines Effectiveness, Logistics and Technology, Oxford University Hospitals NHS Foundation Trust

Chaired by Paul Chrisp, Programme Director, Medicines and Technologies Programme, NICE

Integrating and leading patient-centred systems

  • What system leadership is and why it’s central to STPs
  • Designing new care pathways around patients’ needs
  • Patient-centred care and accountable care systems

​​Nicola Bent, Programme Director, NICE
Dr Rosie Benneyworth, Vice-Chair, NICE 
Dr Kim Holt
, Desginated Doctor and Safeguarding Child Death, Haringey CCG
Chaired by Richard Vize, Director, Public Policy Media Ltd


Implementation workshop - using guidance with limited resources following the NICE recommendation

  • How NICE supports frontline clinicians to implement guidelines and reduce unwarranted variation in care
  • Use of NICE tools to help allocate scarce resources to high impact interventions.
  • How NICE Quality Standards and Indicators can be used to drive quality improvement in particular service areas

Annie Coppel,Associate Director – Field Team (North) and Sector Lead for health, NICE
Chris Connell, Associate Director – Field Team (South) and Sector Lead for social care, NICE
Paula Whitty, Director of Research, Innovation and Clinical Effectiveness, Northumberland,Tyne and Wear NHS Foundation Trust

15:50 – 16:20

Afternoon refreshments and networking

Meet the NICE Field Team

16:20 – 17:15

Future Shock – closing debate

Just as advances, such as genomics and artificial intelligence, are opening up endless possibilities for treatments, the NHS is under severe and growing pressure for funding limitations, workforce shortages and increasing demand.

Can a free at the point of need healthcare system exploit the potential of 21st century care?

How can NICE support clinicians and managers in preparing for the new wave of care?

Professor John Appleby, Director of Research and Chief Economist, Nuffield Trust AHSNs
Professor Andrew Morris, Director, Health Data Research UK
Professor Stephen Powis
, National Medical Director, NHS England
Professor Carole Longson
, Chief Scientific Officer, ABPI
Chaired by Dr Phil Hammond


Chair’s closing remarks and conference close